Abstract:Introduction: There is insufficient understanding on systemic interferon (IFN) responses during COVID-19 infection. Early reports indicated that interferon responses were suppressed by the coronavirus (SARS-CoV-2) and clinical trials of administration of various kinds of interferons had been disappointing. Expression of interferon-stimulated genes (ISGs) in peripheral blood (better known as interferon score) has been a well-established bioassay marker of systemic IFN responses in autoimmune diseases. Therefore, with archival samples of a cohort of COVID-19 patients collected before the availability of vaccination, we aimed to better understand this innate immune response by studying the IFN score and related ISGs expression in bulk and single cell RNAs sequencing expression datasets. Methods: In this study, we recruited 105 patients with COVID-19 and 30 healthy controls in Hong Kong. Clinical risk factors, disease course, and blood sampling times were recovered. Based on a set of five commonly used ISGs (IFIT1, IFIT2, IFI27, SIGLEC1, IFI44L), the IFN score was determined in blood leukocytes collected within 10 days after onset. The analysis was confined to those blood samples collected within 10 days after disease onset. Additional public datasets of bulk gene and single cell RNA sequencing of blood samples were used for the validation of IFN score results. Results: Compared to the healthy controls, we showed that ISGs expression and IFN score were significantly increased during the first 10 days after COVID infection in majority of patients (71%). Among those low IFN responders, they were more commonly asymptomatic patients (71% vs 25%). 22 patients did not mount an overall significant IFN response and were classified as low IFN responders (IFN score < 1). However, early IFN score or ISGs level was not a prognostic biomarker and could not predict subsequent disease severity. Both IFI27 and SIGLEC1 were monocyte-predominant expressing ISGs and IFI27 were activated even among those low IFN responders as defined by IFN score. In conclusion, a substantial IFN response was documented in this cohort of COVID-19 patients who experience a natural infection before the vaccination era. Like innate immunity towards other virus, the ISGs activation was observed largely during the early course of infection (before day 10). Single-cell RNA sequencing data suggested monocytes were the cell-type that primarily accounted for the activation of two highly responsive ISGs (IFI44L and IFI27). Discussion: As sampling time and age were two major confounders of ISG expression, they may account for contradicting observations among previous studies. On the other hand, the IFN score was not associated with the severity of the disease.

Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai

Autoantibodies against type I interferons in COVID-19 infection: a systematic review and meta-analysis

The detectable anti-interferon-γ autoantibodies in COVID-19 patients may be associated with disease severity

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Interferon‐α‐2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease‐2019

Viral Invasion and Type I Interferon Response Characterize the Immunophenotypes During COVID-19 Infection

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients

Serum Levels of Type I Interferon (IFN-I) is Associated with the Severity of COVID-19.

Salivary autoantibodies to type I IFNs: Mirror plasma levels, predispose to severe COVID-19, and enhance feasibility for clinical screening

Prevalence and Characteristics of Rheumatoid-Associated Autoantibodies in Patients with COVID-19

A Chinese Host Genetic Study Discovered Type I Interferons and Causality of Cholesterol Levels and WBC Counts on COVID-19 Severity

Higher expression of monocyte chemotactic protein 1 in mild COVID-19 patients might be correlated with inhibition of Type I IFN signaling

No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients

Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Interferon response and profiling of interferon response genes in peripheral blood of vaccine-naive COVID-19 patients

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells

Longitudinal Profiling of Antibody Response in Patients with COVID-19 in a Tertiary Care Hospital in Beijing, China

Longitudinal single cell atlas identifies complex temporal relationship between type I interferon response and COVID-19 severity

Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection